Breakthrough Clinical Trial Tests Novel Immune-Boosting Therapy
Respiratory virus infections continue to burden healthcare systems nationwide, with over one million Americans hospitalized annually for illnesses including influenza and COVID-19, according to recent Centers for Disease Control and Prevention data. These infections disproportionately affect individuals regularly exposed to young children—who contract respiratory infections more frequently—placing parents, caregivers, teachers, and childcare workers at substantially elevated risk. A groundbreaking clinical trial led by University of Maryland School of Medicine (UMSOM) researchers aims to transform respiratory virus prevention through an innovative intranasal spray designed to strengthen the body’s natural immune defenses.
Understanding the INNA-051 Clinical Investigation
Study Design and Participant Recruitment
The Center for Vaccine Development and Global Health (CVD) at UMSOM is spearheading this randomized, double-blind Phase 2 clinical trial in partnership with ENA Respiratory, the therapy’s manufacturer. Researchers plan to enroll 1,100 healthy adults between ages 18 and 45 who face increased upper respiratory virus exposure through regular contact with young children or frequent close interaction with others in crowded environments.
Study participants will receive random assignment to either the experimental intranasal spray INNA-051 or an inactive placebo spray. This rigorous methodology will determine whether INNA-051 demonstrates superior safety profiles and enhanced effectiveness compared to placebo treatment in boosting immune responses and preventing respiratory illness.
Novel Approach to Respiratory Infection Prevention
“This study represents a new approach to reducing illness from respiratory infections,” explained Dr. Justin Ortiz, Professor of Medicine and respiratory illness specialist serving as UMSOM Principal Investigator for the ongoing trial. “Instead of targeting a single virus, INNA-051 strengthens the body’s early immune defenses, which may help mitigate disease caused by multiple respiratory pathogens.”
How INNA-051 Works: The Science Behind Nasal Immunity
TLR2/6 Agonist Mechanism
Unlike traditional vaccines that target specific viruses, INNA-051 functions as a prophylactic drug administered weekly throughout cold and flu season. This non-vaccine intranasal spray operates as a TLR2/6 agonist, priming the immune system’s frontline defense mechanisms to accelerate pathogen clearance from nasal passages before viruses establish infection.
The therapy’s virus-agnostic design enables potential protection against diverse respiratory viruses—including influenza, common cold viruses, and COVID-19. By acting directly within nasal passages where respiratory viruses initially replicate, INNA-051 targets the critical entry point for airborne infections. Researchers will evaluate whether this prophylactic approach can reduce both illness severity and infection likelihood during peak respiratory virus seasons.
Strengthening Mucosal Immunity: A Paradigm Shift
Addressing Healthcare System Challenges
“Our researchers are aiming to demonstrate the exciting potential of TLR2/6 agonists to become the first prophylactic therapy against respiratory viral illness,” stated UMSOM Dean Dr. Mark T. Gladwin. “Respiratory viruses continue to challenge our healthcare systems because they evade our body’s most fundamental immune barrier—the mucosal surfaces of our airways.”
Future Implications for Public Health
Dr. Gladwin emphasized that preventive approaches strengthening frontline immune defenses could fundamentally transform community viral transmission reduction strategies. This innovation may build enhanced resilience against emerging respiratory threats while reducing hospitalizations, healthcare costs, and disease burden across vulnerable populations.
High-Risk Populations and Preventive Care
Parents, educators, healthcare workers, and caregivers represent prime candidates for prophylactic respiratory virus protection. These individuals experience constant exposure to respiratory pathogens through their professional or family responsibilities, making them ideal participants for evaluating INNA-051’s real-world effectiveness.
The weekly administration schedule during respiratory virus season offers practical convenience compared to daily medications, potentially improving patient adherence and protection consistency throughout high-risk periods.
Moving Toward Broader Respiratory Defense
This clinical trial marks a significant advancement in respiratory virus prevention science, shifting from reactive treatment toward proactive immune enhancement. Success could establish TLR2/6 agonists as cornerstone therapies for seasonal respiratory illness prevention, complementing existing vaccination programs with broad-spectrum protection.
